Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07167537RecruitingPhase 1
Study of OL-CD19-GDT for hard-to-treat autoimmune diseases
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
BeijingAges 18–65 - NCT07172295Recruiting
Low-intensity focused ultrasound for hand tremor
This study uses low-intensity focused ultrasound to stimulate a deep brain area and reduce hand tremors. It is for people with Parkinson's disease, essential tremor, or dystonic tremor whose medications don't work well enough.
Hsinchu, Hsinchu CityAges 18–80 - NCT07173595RecruitingPhase 1
QLS2309 for CD70-positive blood cancers that returned
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT07184307Recruiting
Platelet-rich plasma vs botox for stubborn overactive bladder
This trial compares two treatments for overactive bladder (OAB) that hasn't improved with standard medications: injections of platelet-rich plasma (a substance from your own blood) versus botulinum toxin (Botox). Both are injected into the bladder to help reduce urgency and leakage.
Banhā, Qalyubia GovernorateAges 18 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07193628RecruitingPhase 1
A new immune cell therapy for recurrent glioblastoma
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07198594Recruiting
Fast brain stimulation for hard-to-treat OCD
This study tests a fast-acting brain stimulation method (accelerated rTMS) for people whose obsessive-compulsive disorder has not improved enough with standard treatments. It aims to help those who still have moderate to severe symptoms despite trying multiple medications.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07212244Recruiting
Focused ultrasound for hard-to-treat tremor
This study uses a focused ultrasound treatment guided by MRI to calm hand tremors in people with essential tremor that hasn't responded to medication. It aims to improve daily life by reducing shaking without the need for surgery.
Toronto, OntarioAges 22 years+ - NCT07219407RecruitingPhase 2
Long-term safety study of RAP-219 for focal seizures
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
Boise, IdahoAges 18–70 - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60 - NCT07220876Recruiting
VisiPlate implant for hard-to-control open-angle glaucoma
This trial tests a new device called VisiPlate that is placed in the eye to help lower pressure for people with hard-to-control open-angle glaucoma. It may be an option if standard treatments haven't worked well enough.
Glendale, ArizonaAges 45 years+ - NCT07230600RecruitingPhase 1
Stem cell therapy for thin uterine lining or scarring
This trial tests a new treatment for people with a thin uterine lining or uterine scarring that hasn't responded to other stem cell therapy. It might help improve the lining so pregnancy is possible.
Nanjing, JiangsuAges 22–45 - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,203 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.